Lundbeck, Baxter and La Caixa have contributed to a series C round that will support clinical trials for Sanifit's treatments for dialysis patients.
Spain-based clinical-stage biopharmaceutical company Laboratoris Sanifit raised €36.6m ($41m) in a series C round backed by pharmaceutical companies Lundbeck and Baxter Healthcare yesterday.
Lundbeck participated through its investment subsidiary Lundbeckfond Ventures. The round was led by venture capital firm Ysios Capital and included financial services firm La Caixa, Forbion Capital Partners, and private equity firms Gilde Healthcare and Edmond de Rothschild Investment Partners.
Sanifit was spun out of University of the Balearic Islands in 2007. The company’s lead drug candidate,…
